Skip to main content
TipRanks
Go Ultimate75% OFF

Livzon Pharmaceutical Group (LVZPF) AI Stock Analysis

5 Followers
LVZPF

Livzon Pharmaceutical Group

(Other OTC:LVZPF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Strong ProfitabilitySustained gross and net margins at these levels indicate a profitable pharmaceutical portfolio with meaningful earnings retained from sales. This margin base can support research investment, commercialization and resilience over the next several quarters, provided current products remain competitive.
Negative Factors
Revenue ContractionThe recent revenue decline follows a period of limited growth, indicating that the company is not currently expanding its top line consistently. If this persists, weaker scale benefits could constrain future earnings growth and reduce the resources available for portfolio investment.

Livzon Pharmaceutical Group (LVZPF) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%LVZPF-19.77%SPY+15.52%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$6.06B
Dividend Yield
3.86%
Average Volume (3M)
―
Price to Earnings (P/E)
18.1
Beta (1Y)
0.29
Revenue Growth
-9.78%
EPS Growth
-23.43%
Country
US
Employees
8,878
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Livzon Pharmaceutical Group Business Overview & Revenue Model

Company Description

Livzon Pharmaceutical Group Inc., founded in Zhuhai, China, in 1985, is a prominent enterprise dedicated to the research, development, manufacturing, and global commercialization of a wide range of pharmaceutical products, including finished drugs, a...

Livzon Pharmaceutical Group Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

LVZPF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:3320HK:332079OutperformHKD 27.61B5.867.92%5.45%7.94%52.83%
HK:0867HK:086761NeutralHKD 24.59B13.828.60%3.41%14.80%-2.88%
HK:0874HK:087457NeutralHKD 34.76B14.555.57%6.86%6.00%-23.05%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
HK:0512HK:051255NeutralHKD 15.32B13.466.61%3.92%7.35%-45.49%
HK:3933HK:393354NeutralHKD 14.75B22.893.12%6.33%-12.86%-83.10%

* General Sector Average

Performance Comparison

-40%-20%0%20%LVZPFHK:3933HK:0867HK:0874HK:3320HK:0512Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
LVZPF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
LVZPFLivzon Pharmaceutical Group Class H3.80-0.94-19.77%
HK:3933The United Laboratories International7.49-3.86-34.00%
HK:0867China Medical System Holdings 10.08-3.24-24.31%
HK:0874Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H12.58-5.83-31.66%
HK:3320China Resources Pharmaceutical Group Ltd.4.39-0.24-5.24%
HK:0512Grand Pharmaceutical Group Limited4.32-3.68-46.02%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.